These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 28688781

  • 21. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C, Pancharoen C, Likitnukul S, Luangwedchakarn V, Umrod P, Phasomsap C, Apornpong T, Chuanchareon T, Butterworth O, Puthanakit T.
    Vaccine; 2011 Aug 11; 29(35):5886-91. PubMed ID: 21729732
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Kosina P.
    Vaccine; 2017 Sep 12; 35(38):5186-5193. PubMed ID: 28797727
    [Abstract] [Full Text] [Related]

  • 23. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
    Togashi T, Okada K, Yamaji M, Thompson A, Gurtman A, Cutler M, Aizawa M, Gruber WC, Scott DA.
    Pediatr Infect Dis J; 2015 Oct 12; 34(10):1096-104. PubMed ID: 26121200
    [Abstract] [Full Text] [Related]

  • 24. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules.
    Moïsi JC, Yaro S, Kroman SS, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade BM, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo JB, Gessner BD.
    J Pediatric Infect Dis Soc; 2019 Nov 06; 8(5):422-432. PubMed ID: 30299491
    [Abstract] [Full Text] [Related]

  • 25. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.
    Martinón-Torres F, Czajka H, Center KJ, Wysocki J, Majda-Stanislawska E, Omeñaca F, Bernaola Iturbe E, Blazquez Gamero D, Concheiro-Guisán A, Gimenez-Sanchez F, Szenborn L, Giardina PC, Patterson S, Gruber WC, Scott DA, Gurtman A.
    Pediatrics; 2015 Apr 06; 135(4):e876-86. PubMed ID: 25780077
    [Abstract] [Full Text] [Related]

  • 26. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.
    van Westen E, Wijmenga-Monsuur AJ, van Dijken HH, van Gaans-van den Brink JA, Kuipers B, Knol MJ, Berbers GA, Sanders EA, Rots NY, van Els CA.
    Clin Infect Dis; 2015 Aug 01; 61(3):342-9. PubMed ID: 25838290
    [Abstract] [Full Text] [Related]

  • 27. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD, Canadian PCV13 Study Group.
    Pediatr Infect Dis J; 2012 Jan 01; 31(1):72-7. PubMed ID: 21960186
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era.
    Prins-van Ginkel AC, Berbers GA, Grundeken LH, Tcherniaeva I, Wittenberns JI, Elberse K, Mollema L, de Melker HE, Knol MJ.
    PLoS One; 2016 Jan 01; 11(1):e0147437. PubMed ID: 26796783
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13®) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDS.
    Makenga G, Mtove G, Yin JK, Mziray A, Bwana VM, Kisinza W, Mjema J, Amos B, Antony L, Shingadia D, Oftadeh S, Booy R.
    Front Immunol; 2021 Jan 01; 12():673392. PubMed ID: 34220819
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.
    Idoko OT, Mboizi RB, Okoye M, Laudat F, Ceesay B, Liang JZ, Le Dren-Narayanin N, Jansen KU, Gurtman A, Center KJ, Scott DA, Kampmann B, Roca A.
    Vaccine; 2017 May 31; 35(24):3256-3263. PubMed ID: 28479175
    [Abstract] [Full Text] [Related]

  • 35. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R, Hurley D, Grayson S, Li J, Nolan K, McFetridge RD, Hartzel J, Abeygunawardana C, Winters M, Pujar H, Benner P, Musey L.
    Hum Vaccin Immunother; 2019 May 31; 15(3):549-559. PubMed ID: 30689507
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F.
    Vaccine; 2019 Feb 14; 37(8):1021-1029. PubMed ID: 30685252
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L.
    Pediatr Infect Dis J; 2009 Apr 14; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [Abstract] [Full Text] [Related]

  • 39. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 40. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Traskine M, Gardev A, Song Y, Borys D.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.